Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sacituzumab Tirumotecan · MK-2870, SKB-264

Antibody-drug conjugate · Cytotoxic, directed at TROP2 (TACSTD2) · developed by Merck &

Phase 3 Most advanced trial

MRK Developer

1 Registered trials

What is Sacituzumab Tirumotecan?

Sacituzumab tirumotecan is an antibody-drug conjugate composed of a humanized IgG1 monoclonal antibody targeting TROP2 conjugated to tirumotecan, a topoisomerase I inhibitor. Upon binding to TROP2 on tumor cells, the linker is cleaved and tirumotecan is released to inhibit DNA topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in cervical cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-2870, SKB-264, sac-TMT
Drug type: Antibody-drug conjugate
Targets: TROP2 (TACSTD2)
Mechanism: Cytotoxic, directed at TROP2 (TACSTD2)
Pathways: DNA topoisomerase I inhibition, apoptosis, cell cycle arrest
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 3DV5TD1VL3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07216703	Phase 3	Cervical Cancer	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical Cancer

Other drugs acting on TACSTD2

Datopotamab Deruxtecan FDA approved Sacituzumab Govitecan FDA approved PBI-410 Phase 1/2

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Sacituzumab Tirumotecan

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z